Treatment of spinocerebellar ataxia with buspirone
- PMID: 17512011
- DOI: 10.1016/j.jns.2007.04.019
Treatment of spinocerebellar ataxia with buspirone
Abstract
Preliminary data suggest potential benefit of 5-HT receptor agonists in the treatment of ataxias. We studied the effects of buspirone in a cohort of twenty patients with spinocerebellar ataxia (SCA). Twenty patients were treated in this double-blind, placebo controlled, cross-over trial with either buspirone HCl 30 mg twice daily or placebo for 3 months. Buspirone was not shown to be superior to placebo in the treatment of patients with SCA.
Comment in
-
Buspirone and serotonin in spinocerebellar ataxia.J Neurol Sci. 2008 May 15;268(1-2):199-200; author reply 200-1. doi: 10.1016/j.jns.2007.12.008. Epub 2008 Jan 28. J Neurol Sci. 2008. PMID: 18222483 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
